SCRIP
CITELINE COMMERCIAL

21 Mar 2022 | **News**

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: clinical setbacks in melanoma and prostate cancer; Chinese pharma firms face US listing pressures; Eisai hands Aduhelm to Biogen; and *Scrip Asks* what 2022 holds for digital and telehealth.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip*'s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 18 March 2022, including: clinical setbacks in melanoma and prostate cancer; Chinese pharma firms face US listing pressures; *Eisai Co., Ltd.* hands Aduhelm to *Biogen, Inc.*; and *Scrip Asks* what 2022 holds for digital and telehealth.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on *Apple Podcasts*, *Google Podcasts*, *SoundCloud*, *TuneIn* and *Spotify Podcasts*, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "*Nektar/BMS's IL-2 Inhibitor Melanoma Failure Leaves Room For Other Contenders*" - Scrip, 14 Mar, 2022.)

(Also see "*Rare Setback For Merck & Co And AstraZeneca's Keytruda-Lynparza Combo In Prostate Cancer*" - Scrip, 16 Mar, 2022.)

(Also see "*Financial Decoupling: China Biotechs Brace For Potential US Delistings, Softening Economy*" - Scrip, 16 Mar, 2022.)

(Also see "*Eisai Gives Full Aduhelm Responsibility To Biogen Under Amended Agreement*" - Scrip, 14

© Citeline 2024. All rights reserved.

Mar, 2022.)

(Also see "*Scrip Asks...What Does 2022 Hold For Biopharma? Part 6: Digital And Telehealth*" - Scrip, 16 Mar, 2022.)

Click here to explore this interactive content online

© Citeline 2024. All rights reserved.